Ecotoxicology and Environmental Safety 2012-01-01

Influences of two antibiotic contaminants on the production, release and toxicity of microcystins

Ying Liu, Baoyu Gao, Qinyan Yue, Yuntao Guan, Yan Wang, Lihui Huang

文献索引:Ecotoxicol. Environ. Saf. 77 , 79-87, (2012)

全文:HTML全文

摘要

The influences of spiramycin and amoxicillin on the algal growth, production and release of target microcystins (MCs), MC-LR, MC-RR and MC-YR, in Microcystis aeruginosa were investigated through the seven-day exposure test. Spiramycin were more toxic to M. aeruginosa than amoxicillin according to their 50 percent effective concentrations (EC 50) in algal growth, which were 1.15 and 8.03 μg/l, respectively. At environmentally relevant concentrations of 100 ng/l–1 μg/l, spiramycin reduced the total MC content per algal cell and inhibited the algal growth, while exposure to amoxicillin led to increases in the total MC content per algal cell and the percentage of extracellular MCs, without affecting the algal growth. Toxicity of MCs in combination with each antibiotic was assessed in the luminescent bacteria test using the toxic unit (TU) approach. The 50 percent effective concentrations for the mixtures (EC 50 mix ) were 0.56 TU and 0.48 TU for MCs in combination with spiramycin and amoxicillin, respectively, indicating a synergistic interaction between MCs and each antibiotic (EC 50 mix <1 TU). After seven-day exposure to 100 ng/l–1 μg/l of antibiotics, spiramycin-treated algal media and amoxicillin-treated algal media showed significantly lower ( p<0.05) and higher ( p<0.05) inhibition on the luminescence of Photobacterium phosphoreum, respectively, compared with the untreated algal medium. These results indicated that the toxicity of MCs were alleviated by spiramycin and enhanced by amoxicillin, and the latter effect would increase threats to the aquatic environment.


相关化合物

  • 螺旋霉素

相关文献:

Regulation of the biosynthesis of the macrolide antibiotic spiramycin in Streptomyces ambofaciens.

2010-11-01

[J. Bacteriol. 192(21) , 5813-21, (2010)]

A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.

2012-04-01

[J. Pain Symptom Manage. 43(4) , 679-93, (2012)]

Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.

2012-04-01

[Antimicrob. Agents Chemother. 56(4) , 1762-8, (2012)]

Antioxidant responses and degradation of two antibiotic contaminants in Microcystis aeruginosa.

2012-12-01

[Ecotoxicol. Environ. Saf. 86 , 23-30, (2012)]

Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance.

1998-04-01

[Clin. Pharmacokinet. 34(4) , 303-10, (1998)]

更多文献...